Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Notifiable Agents according to RKI - Erregerliste RKI

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 1 Elemento de dados, 2 Idiomas

Grupo de itens: Notifiable Agent

Notifiable Agents according to RKI. ODM created by Prof. Dr. Martin Dugas. Semantic annotation created by Prof. Dr. Sylvia Thun and Prof. Dr. Martin Digas

Study SHIP-TREND_TREND1_PIA - t1.signinfect2

- 26/10/2024 - 26 Formulários, 1 Grupo de itens, 6 Elementos de dados, 2 Idiomas

Grupo de itens: t1.signinfect2

SHIP Study https://doi.org/10.1093/ije/dyac034

t1.pia_impact

1 Grupo de itens 75 Elementos de dados

Mostrar mais

Infectious Disease Markers NHLBI - Lab Infectious Disease Markers ISO Date Format Version 1 2004

- 20/09/2021 - 1 Formulário, 14 Grupos de itens, 48 Elementos de dados, 1 Idioma

Grupos de itens: Registry Use Only, Identification Data, HSCT Type , Product Type, Source Information, Hepatitis B Virus, Hepatitis C Virus, Human T-Lymphotropic Virus, Human Immunodeficiency Virus, Syphilis, Cytomegalovirus, West Nile Virus, Infectious Disease Marker, Author Information

Infectious Disease Markers Uses The ISO Date Format Version 1 Lab - 2004 - Infectious Disease Markers ISO Date Format Version 1 - 2884169v1.0 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6A861230-7A94-FE96-E040-BB89AD434611

Lab - 2004 - Infectious Disease Markers - 2630454v6.0 - 2004 - Infectious Disease Markers

- 20/09/2021 - 1 Formulário, 17 Grupos de itens, 48 Elementos de dados, 1 Idioma

Grupos de itens: Registry Use Only, Identification Data Part 1 of 4, Identification Data Part 2 of 4, Identification Data Part 3 of 4, Identification Data Part 4 of 4 , HSCT Type , Product Type, Source Information, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) , Human T-Lymphotropic Virus , Human Immunodeficiency Virus (HIV) , Syphilis , Cytomegalovirus (CMV), West Nile Virus (WNV) , Other Infectious Disease Marker, Author Information

Infectious Disease Markers Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=62093463-23EF-B53C-E040-BB89AD434539

GSK TWINRIX™ Hepatitis A and B Vaccine: Persistence of Immune Response in 0,6 Month vs. 0,1,6 Month Schedule NCT00197119 - Longterm Follow-up Visit 13

- 17/09/2021 - 1 Formulário, 6 Grupos de itens, 23 Elementos de dados, 1 Idioma

Grupos de itens: Informed consent, Demographics, Laboratory Tests, Follow-up studies, Investigator signature, Tracking Document Reason for non participation

GSK TWINRIX™ Hepatitis A and B Vaccine: Persistence of Immune Response in 0,6 Month vs. 0,1,6 Month Schedule NCT00197119 - Longterm Follow-up VISIT 13 - YEAR 8 - 96 MONTHS + 2 MONTHS Study ID: 100566 Clinical Study ID: 100566 Study Title: Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00197119 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: BIO HAB; Twinrix Study Indication: Hepatitis A; Hepatitis B